Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug
- Tickers:
- N/A
Jim Boeheim and Cellceutix (CTIX) Team to Fight Cancer
Clinical trials should be starting at Harvard's Dana-Farber Cancer Center in the next two months as Cellceutix looks to validate their laboratory research on Kevetrin, their novel drug in development for the treatment of drug resistant cancers. Yesterday, it was disclosed that Syracuse basketball icon Jim Boeheim has come on board the Cellceutix team in the fight against cancer.
- Tickers:
- N/A
Magic Formula Investing Weekly Roundup 4/29/2012
(PRXI, GAI, LLY) PennyOmega.com Watch List for Monday Apr. 09, 2012
Magic Formula Investing Weekly Roundup 3/4/2012
(FLS, UHS, CRWE, LLY) Featured Stock by DoubleInStocks.com
Strange Volume of Eli Lilly - NYSE:LLY
Eli Lilly & Co (NYSE:LLY) discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co witnessed volume of 31.14 million shares during last trade however it holds an average trading capacity of 7.68 million shares.
Eli Lilly Non Normal Trade in last session - NYSE:LLY
Eli Lilly & Co (NYSE:LLY) discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co witnessed volume of 26.02 million shares during last trade however it holds an average trading capacity of 7.36 million shares.
- Tickers:
- LLY
- Tags:
- General Market News, LLY, NYSE:LLY, Eli Lilly
Magic Formula Investing Weekly Roundup 1/29/2012
Cellceutix (CTIX) Makes Another Breakthrough in Cancer Research
Cellceutix Corporation (OTCBB:CTIX) has regularly reported significant breakthroughs in cancer research through studies of Kevetrin, the company’s novel cancer drug in development. Amazing data has been collected by Cellceutix researchers testing Kevetrin against many cancer lines, including head & neck, prostate, lung, colon, pancreatic and leukemia.
- Tickers:
- N/A
Eli Lilly & Co with Positive Gains - NYSE:LLY
Eli Lilly & Co (NYSE:LLY) discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co achieved its new price of $42.03 where it was opened at $41.95 up 0.24 points or +0.58% by closing at $41.80.
- Tickers:
- LLY
- Tags:
- General Market News, LLY, NYSE:LLY, Eli Lilly
Eli Lilly & Co Stocks Ended in Red - NYSE:LLY
Eli Lilly & Co. (NYSE:LLY) Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. It also has an animal health business segment. Eli Lilly & Co. achieved its new 52 week high price of $41.86 where it was opened at $41.77 down -0.11 points or -0.26% by closing at $41.46.
- Tickers:
- LLY
- Tags:
- General Market News, LLY, NYSE:LLY, Eli Lilly
(SOL, PFE, MJGCF, LLY) Stock Report from DrStockPick.com
ReneSola Ltd. (NYSE:SOL) a leading global manufacturer of solar products, announced the completion and grid connection of the Company's 20 megawatt ("MW") solar power plant in Wulan County in Qinghai, China with the Company providing all 20 MW of solar modules. The solar power plant is the first of its kind for ReneSola.



